E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Doman of EGFR |
Cáncer colorrectal metastásico y resistencia adquirida a anticuerpos monoclonales anti-EGFR y con mutación documentada del dominio extracelular del EGFR (ECD-EGFR) |
|
E.1.1.1 | Medical condition in easily understood language |
Metastatic Colorectal Cancer |
Cáncer colorrectal metastásico |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of the weekly dosing regimen (9 mg/kg loading dose followed by 6 mg/kg/week dose) of Sym004 in terms of overall response rate (ORR) in patients with mCRC harboring ECD-EGFR mutations |
evaluar la eficacia de la pauta posológica semanal (dosis de carga de 9 mg/kg seguida de dosis semanal de 6 mg/kg) de Sym004 en cuanto a la tasa de respuesta general (TRG) en pacientes con cáncer colorrectal metastásico (CCRm) que presentan mutaciones del dominio extracelular del receptor del factor de crecimiento epidérmico (ECD-EGFR) |
|
E.2.2 | Secondary objectives of the trial |
• To assess efficacy in terms of duration of response (DOR), progression-free survival (PFS), time-to-treatment failure (TTF), and overall survival (OS) • To determine the safety profile of the weekly dosing regimen • To evaluate the dose intensity for the weekly dosing regimen • To evaluate pharmacokinetics and immunogenicity of Sym004 |
• Evaluar la eficacia en cuanto a la duración de la respuesta (DR), la supervivencia sin progresión (SSP), el tiempo hasta el fracaso del tratamiento (TFT) y la supervivencia general (SG) • Determinar el perfil de seguridad de la pauta posológica semanal • Evaluar la intensidad de la dosis de la pauta posológica semanal • Evaluar la farmacocinética (FC) y la inmunogenicidad de Sym004 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Written informed consent obtained before undergoing any study-related activities • Male or female, at least 18 years of age • Histologically or cytologically confirmed locally advanced or metastatic CRC that is documented to be without KRAS or NRAS gene mutations (i.e. tumors must express the KRAS and NRAS wild type (WT) exon 2, 3, and 4) • Identification of any ECD-EGFR mutation in blood sample • Failure of or intolerance to all of the following a. Fluorouracil (5-FU) b. Oxaliplatin c. Irinotecan • Previous treatment with bevacizumab and/or ziv-aflibercept is allowed, but not mandatory. • “Acquired resistance” to marketed anti-EGFR mAbs a. Response while on previous treatment with marketed anti-EGFR mAb, defined as i. Partial response (PR) or complete response (CR) and/or ii. Stable disease (SD) for more than 16 weeks b. Documented progressive disease (PD) during or within 3 calendar months after cessation of previous anti-EGFR mAb treatment • No more than 3 calendar months from last dose of previous anti-EGFR mAb to time of consent • Measurable disease defined as one or more target lesions according to RECIST 1.1 • Life expectancy of at least 3 months • ECOG PS ≤ 1 |
• Consentimiento informado por escrito otorgado antes de realizar cualquier actividad relacionada con el estudio. • Edad mínima de 18 años, ya se trate de un hombre o una mujer. • Confirmación histológica o citológica de CCR localmente avanzado o metastásico que haya sido documentado sin mutaciones del gen KRAS o NRAS (es decir, los tumores deben expresar el gen KRAS o NRAS de tipo natural [wild type, WT], exones 2, 3 y 4) • Identificación de cualquier mutación ECD-EGFR en la muestra de sangre • Fracaso de todos estos medicamentos o intolerancia a ellos: a. Fluorouracilo (5-FU) b. Oxaliplatino c. Irinotecán • Se permite un tratamiento previo con bevacizumab o ziv-aflibercept, pero no es obligatorio. • “Resistencia adquirida” a los ACM anti-EGFR comercializados a. En un tratamiento anterior con ACM anti-EGFR comercializados, respuesta definida como: i. Respuesta parcial (RP) o respuesta completa (RC), o ii. Enfermedad estable (EE) durante más de 16 semanas b. Enfermedad progresiva (EP) documentada durante 3 meses naturales o en un plazo de 3 meses tras la interrupción de un tratamiento previo con ACM anti-EGFR. • No más de 3 meses naturales transcurridos desde la última dosis del tratamiento previo con ACM anti-EGFR hasta el momento del consentimiento • Enfermedad medible definida como una o más lesiones diana según los RECIST 1.1 • Expectativa de vida de, por lo menos, 3 meses. • EG ECOG ≤ 1 |
|
E.4 | Principal exclusion criteria |
• Intake of any investigational drug or any anticancer therapy in the 28 days (or 5 half-lives for noncytotoxics, whichever is shorter) before the first dose of IMP • Previous treatment with Sym004, TAS-102 (trifluridine and tipiracil [Lonsurf®]) and/or regorafenib [Stivarga®] • Patients who in the opinion of the Investigator would benefit more from regorafenib or Lonsurf® treatment (except where regorafenib or Lonsurf® are not reimbursed in the country) • Diarrhea Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 at Screening (Step 1) • Skin rash CTCAE Grade >1 from previous anti-EGFR therapy at Screening (Step 1) • Magnesium <0.9 mg/dL • Abnormal organ or bone marrow function |
• Administración de cualquier tratamiento antineoplásico o cualquier fármaco en investigación durante los 28 días anteriores a la primera dosis del PEI (o 5 semividas para los no citotóxicos, lo que ocurra antes). • Tratamiento previo con Sym004, TAS-102 (trifluridina y tipiracilo [Lonsurf®]) o regorafenib [Stivarga®] • Pacientes que, según la opinión del investigador, se beneficiarían más con un tratamiento con regorafenib o Lonsurf® (excepto en el caso en que no se reembolse el coste de regorafenib o Lonsurf® en el país) • Grado de diarrea según los Criterios terminológicos comunes para acontecimientos adversos (Common Terminology Criteria for Adverse Events, CTCAE) > 1 en la selección (paso 1) • Grado de erupción cutánea según CTCAA > 1 en tratamiento anti-EGFR previo en la selección (paso 1) • Magnesio < 0,9 mg/dl • Función anómala de la médula ósea o de algún órgano |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Documented best overall response (OR), assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on Investigator assessment. |
la mejor respuesta general (RG) documentada, evaluada por los Criterios de evaluación de respuesta en tumores sólidos (Response Evaluation Criteria in Solid Tumors, RECIST) v1.1 según la evaluación del investigador |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Response (CR, PR, PD, or SD) will initially be evaluated per RECIST v1.1 by the Investigator. All scans from responders from Stage 1 of the trial will be subject for central evaluation at the timepoint of the futility assessment and all the rest will be evaluated at the end of the trial |
Respuesta (RC,RP,EP o EE) será incialmente evaluado por RECIST por el Investigador. Todos los escaners |
|
E.5.2 | Secondary end point(s) |
• DOR, which is defined as time from first documentation of tumor response (complete response [CR] or partial response [PR]) to disease progression • PFS, which is defined as the duration from the first dose of Sym004 until first event, where an event can be a progression (radiological confirmation or clinical progression) or death due to any cause, where death will only be considered as an event if it occurs within 12 weeks after last tumor response assessment without progression • TTF, which is defined as time from the first dose until discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death • OS, which is defined as the time from the first dose to the date of death. If a patient has not died, his survival time will be censored at the last date he was known to be alive • Pharmacokinetic (PK) parameters for Sym004 describing systemic exposure, half-life, clearance, and volume of distribution |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
DOR is defined as time from first documentation of tumor response to disease progression PFS is defined as the duration from the first dose of Sym004 until first event, where an event can be a progression or death due to any cause, where death will only be considered as an event if it occurs within 12 weeks after last tumor response assessment without progression TTF is defined as time from the first dose until discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death OS is defined as the time from the first dose to the date of death. If a patient has not died, his survival time will be censored at the last date he was known to be alive PK - throughout study until end of treatment visit |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity |
Inmunogenicidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the complete trial is defined as last patient’s last visit (End-of-Trial Visit) or until last patient on treatment has completed 52 weeks on treatment, whichever is earlier. |
El final del ensayo completado se define como la última visita del último paciente (visita final del ensayo) o hasta que el último paciente haya completado 52 semanas de tratamiento, cualquierea que sea antes. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |